补脾益肠丸治疗溃疡性结肠炎的研究

发布时间：2018-05-29 16:27

本文选题：溃疡性结肠炎 + 缓解期　；参考：《青岛大学》2017年硕士论文

【摘要】：目的:评估补脾益肠丸在溃疡性结肠炎中的治疗效果以及安全性,为其在溃疡性结肠炎中的使用奠定理论基础。方法:选取2015年1月~2016年9月在潍坊市市立医院、潍坊市第二人民医院诊治的118例溃疡性结肠炎患者展开研究,入组标准为:符合西医诊断标准无发热及需要治疗的肠外症状和全身症状者,且病变侵及乙状结肠以上者,除外服用其他疾病的药物有可能影响研究结果者;按中医诊断标准除外热毒炽盛型患者,所有患者按照就诊顺序随机编号为1-118号,奇数号者为治疗组,偶数号者为对照组。其中治疗组和对照组各59例。对照组患者采用始终应用5氨基水杨酸治疗;治疗组在对照组基础上急性症状缓解后(中医证候积分小于等于2分)加用补脾益肠丸治疗,2个月为1个疗程,完成2个疗程的治疗后通过比较两组治疗前后证候疗效,肠镜下粘膜表现,血沉、C反应蛋白水平、CD4+、CD8+水平以及血常规、肝功、肾功、凝血常规等观察补脾益肠丸在溃疡性结肠炎中的疗效及安全性。研究所得数据采用SPSS15.0专业统计学软件进行分析检验。结果:(1)两组基线指标各项数据、性别比例、病程、年龄、中医证候积分比较无明显统计学差异,(P0.05);(2)中医证候疗效比较:治疗组为91.53%高于对照组的79.66%,统计学差异显著,(P0.05);(3)血沉、C反应蛋白比较:治疗后与治疗前组内比较血沉、C反应蛋白均降低,统计学差异显著,(P0.05);治疗后组间比较,治疗组低于对照组,统计学差异显著,(P0.05);(4)治疗后与治疗前组内比较:CD4+平均水平、CD8+平均水平均有显著变化,统计学差异显著,(P0.05);治疗后两组间比较治疗组CD4+低于对照组,CD8+高于对照组,统计学差异显著,(P0.05);(5)CD4+、CD8+治疗前后数值变化值比较:治疗组高于对照组,组间差异显著,(P0.05);(6)肠镜检查黏膜病变疗效比较:治疗组总有效率为83.05%高于对照组的67.80%,统计学差异显著,(P0.05);(7)安全性评价:疗程中治疗组出现3例不良反应,对照组5例出现不良反应,经对症处理后症状改善。两组均未出现明显血常规、凝血、肝、肾功能异常。结论:补脾益肠丸对溃疡性结肠炎的治疗取得显著成效,其治疗内在机制可能是通过对机体的CD4+、CD8+进行调节,修复受损溃疡面,加速治愈疾病。
[Abstract]:Objective: To evaluate the therapeutic effect and safety of Bu PI Yichang pill in ulcerative colitis, and to lay a theoretical foundation for its use in ulcerative colitis. Methods: to select 118 cases of ulcerative colitis in Weifang city hospital in January 2015 and second people's Hospital in Weifang, Weifang City, Second People's hospital. Those who are in accordance with the diagnostic criteria of Western medicine have no fever and need to be treated for extra intestinal symptoms and systemic symptoms, and those with the exception of the sigmoid colon, except for other diseases, may affect the results of the study. Except for the hot toxic type of patients with the exception of the TCM diagnostic standard, all the patients are numbered 1-118 and the odd number is numbered. For the treatment group, the even number was the control group, with 59 cases in the treatment group and the control group. The control group was treated with 5 amino salicylic acid, and the treatment group was treated with the treatment of the acute symptom (TCM syndrome score less than 2 points) on the basis of the control group (the TCM syndrome score was less than 2 points) and the 1 course of treatment for 2 months. The treatment group completed the 2 course of treatment after the treatment. The curative effect and safety of the two groups were compared before and after treatment. The results were as follows: (1) the efficacy and safety of supplementing spleen Yichang pills in ulcerative colitis were observed. The results were as follows: the effect and safety of the spleen Yichang pill in ulcerative colitis. The results were as follows: (1) the results of the two groups were analyzed and tested. There was no significant difference between the two groups of baseline indicators, sex ratio, course of disease, age and TCM syndrome score, (P0.05); (2) the curative effect of TCM syndrome was compared: the treatment group was 91.53% higher than that of the control group (79.66%), the statistical difference was significant, (P0.05); (3) erythrocyte sedimentation rate, C reactive protein comparison: after treatment and before treatment group, C reactive protein was compared. Both decreased, statistical difference was significant (P0.05); compared with the control group after treatment, the treatment group was lower than the control group, with significant difference (P0.05); (4) the average level of CD4+ and the average level of CD8+ were significantly changed after treatment. The statistical difference was significant, (P0.05); the CD4+ in the treatment group was lower than the control group after treatment, and CD8+ was higher than that of the control group. CD8+ was higher than that of the control group. In the control group, the statistical difference was significant (P0.05); (5) the values of CD4+ and CD8+ were compared before and after the treatment: the treatment group was higher than the control group, and the difference between the groups was significant, (P0.05); (6) the curative effect of the colonoscopy was compared with the control group: the total effective rate of the treatment group was 83.05% higher than that of the control group, (P0.05); (7) the safety evaluation: treatment during the course of treatment. There were 3 cases of adverse reactions in the group, 5 cases in the control group had adverse reactions, and the symptoms improved after treatment. The two groups had no obvious blood routine, coagulation, liver and kidney function. Conclusion: the treatment of ulcerative colitis is remarkable. The internal mechanism of the treatment may be adjusted by the CD4+ and CD8+ of the body. Damage the ulcer surface and accelerate the cure of the disease.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259

【参考文献】